I Mab Stock Today
| IMAB Stock | USD 0.87 0 0.13% |
PerformanceVery Weak
| Odds Of DistressQuite High
|
I Mab is trading at 0.8711 as of the 25th of March 2025, a 0.13 percent increase since the beginning of the trading day. The stock's open price was 0.87. I Mab has more than 62 % chance of experiencing financial distress in the next few years of operation. It also generated negative returns for investors over the last 90 days. The performance scores are derived for the period starting the 23rd of February 2025 and ending today, the 25th of March 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 17th of January 2020 | Category Healthcare | Classification Health Care |
I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. The company was founded in 2014 and is headquartered in Shanghai, the Peoples Republic of China. I-Mab ADR operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 77.58 M outstanding shares of which 935.95 K shares are currently shorted by private and institutional investors with about 1.1 trading days to cover. More on I Mab
Moving against IMAB Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
IMAB Stock Highlights
| Director CEO | XiYong MBA | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Debt LevelsI Mab can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand I Mab's financial leverage. It provides some insight into what part of I Mab's total assets is financed by creditors.
LiquidityI Mab currently holds 18.89 M in liabilities with Debt to Equity (D/E) ratio of 0.03, which may suggest the company is not taking enough advantage from borrowing. I Mab has a current ratio of 7.16, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about I Mab's use of debt, we should always consider it together with its cash and equity.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
I Mab (IMAB) is traded on NASDAQ Exchange in USA. It is located in 2440 Research Boulevard, Rockville, MD, United States, 20850 and employs 220 people. I Mab is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 85.74 M. I Mab conducts business under Biotechnology sector and is part of Health Care industry. The entity has 77.58 M outstanding shares of which 935.95 K shares are currently shorted by private and institutional investors with about 1.1 trading days to cover.
I Mab currently holds about 3.92 B in cash with (1.3 B) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 47.2, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check I Mab Probability Of Bankruptcy
Ownership AllocationI Mab has a total of 77.58 Million outstanding shares. 30% of I Mab outstanding shares are owned by outside corporations. Institutional investors are typically referred to investors that purchase positions in a given stock to benefit from reduced commissions. Hence, institutional investors are subject to different rules and regulations than regular investors. Please look out for any change in current institutional holding as this could mean something significant has changed at the company or is about to change. Please note that no matter how many assets the company holds, if the real value of the entity is less than the current market value, you may not be able to make money on it.
Check IMAB Ownership Details
IMAB Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Alberta Investment Management Corp | 2024-12-31 | 74.7 K | |
| Renaissance Technologies Corp | 2024-12-31 | 63.8 K | |
| Dimensional Fund Advisors, Inc. | 2024-12-31 | 58.4 K | |
| Barclays Plc | 2024-12-31 | 30.4 K | |
| Mariner Wealth Advisors Llc | 2024-12-31 | 28.8 K | |
| Geode Capital Management, Llc | 2024-12-31 | 22 K | |
| Hrt Financial Llc | 2024-12-31 | 13.1 K | |
| Goldman Sachs Group Inc | 2024-12-31 | 10.7 K | |
| Freestone Capital Holdings, Llc | 2024-12-31 | 10 K | |
| Hillhouse Capital Advisors, Ltd. | 2024-12-31 | 6 M | |
| Morgan Stanley - Brokerage Accounts | 2024-12-31 | 3.5 M |
I Mab Historical Income Statement
IMAB Stock Against Markets
I Mab Corporate Management
| Louie MD | Interim Officer | Profile | |
| Richard MBA | COO CFO | Profile | |
| Weiming Tang | Executive Officer | Profile | |
| Jerry Wang | CoFounder Officer | Profile | |
| Cheng Li | Chief Officer | Profile | |
| Skelton Joseph | Chief Officer | Profile |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in I Mab. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. For information on how to trade IMAB Stock refer to our How to Trade IMAB Stock guide.You can also try the Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of I Mab. If investors know IMAB will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about I Mab listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.16) | Revenue Per Share | Quarterly Revenue Growth (0.62) | Return On Assets | Return On Equity |
The market value of I Mab is measured differently than its book value, which is the value of IMAB that is recorded on the company's balance sheet. Investors also form their own opinion of I Mab's value that differs from its market value or its book value, called intrinsic value, which is I Mab's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because I Mab's market value can be influenced by many factors that don't directly affect I Mab's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between I Mab's value and its price as these two are different measures arrived at by different means. Investors typically determine if I Mab is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, I Mab's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.